- Home
- RDHL vs XRTX Comparison
RDHL vs XRTX Comparison
Compare RDHL & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- XRTX
- Stock Information
- Founded
- RDHL 2009
- XRTX 2011
- Country
- RDHL Israel
- XRTX Canada
- Employees
- RDHL N/A
- XRTX N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- XRTX Pharmaceuticals and Biotechnology
- Sector
- RDHL Health Care
- XRTX Health Care
- Exchange
- RDHL Nasdaq
- XRTX Nasdaq
- Market Cap
- RDHL 4.3M
- XRTX 3.4M
- IPO Year
- RDHL N/A
- XRTX N/A
- Fundamental
- Price
- RDHL $2.18
- XRTX $0.89
- Analyst Decision
- RDHL
- XRTX
- Analyst Count
- RDHL 0
- XRTX 0
- Target Price
- RDHL N/A
- XRTX N/A
- AVG Volume (30 Days)
- RDHL 17.8K
- XRTX 225.4K
- Earning Date
- RDHL 08-28-2025
- XRTX 08-13-2025
- Dividend Yield
- RDHL N/A
- XRTX N/A
- EPS Growth
- RDHL N/A
- XRTX N/A
- EPS
- RDHL N/A
- XRTX N/A
- Revenue
- RDHL $8,042,999.00
- XRTX N/A
- Revenue This Year
- RDHL $381.91
- XRTX N/A
- Revenue Next Year
- RDHL N/A
- XRTX N/A
- P/E Ratio
- RDHL N/A
- XRTX N/A
- Revenue Growth
- RDHL 23.17
- XRTX N/A
- 52 Week Low
- RDHL $1.71
- XRTX $0.80
- 52 Week High
- RDHL $20.28
- XRTX $2.98
- Technical
- Relative Strength Index (RSI)
- RDHL 65.22
- XRTX 50.40
- Support Level
- RDHL $2.00
- XRTX $0.81
- Resistance Level
- RDHL $2.08
- XRTX $0.99
- Average True Range (ATR)
- RDHL 0.09
- XRTX 0.08
- MACD
- RDHL 0.03
- XRTX 0.01
- Stochastic Oscillator
- RDHL 97.73
- XRTX 47.37
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.